Eesti -
eesti -
Ravimiamet
alendronic acid/colecalciferol mylan tablett
mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+2800rÜ 12tk; 70mg+2800rÜ 4tk
Eesti -
eesti -
Ravimiamet
alendronic acid/colecalciferol teva tablett
teva pharma b.v. - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 16tk; 70mg+5600rÜ 12tk; 70mg+5600rÜ 24tk; 70mg+5600rÜ 4tk; 70mg+5600rÜ 28tk
Eesti -
eesti -
Ravimiamet
alendronic acid/ colecalciferol sandoz tablett
sandoz pharmaceuticals d.d. - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 4tk; 70mg+5600rÜ 6tk; 70mg+5600rÜ 2tk; 70mg+5600rÜ 12tk
Eesti -
eesti -
Ravimiamet
alendronic acid/colecalciferol zentiva tablett
zentiva k.s. - alendroonhape+kolekaltsiferool - tablett - 70mg+2800rÜ 4tk; 70mg+2800rÜ 12tk
Eesti -
eesti -
Ravimiamet
alendronic acid/colecalciferol mylan tablett
mylan pharmaceuticals limited - alendroonhape+kolekaltsiferool - tablett - 70mg+5600rÜ 12tk
Eesti -
eesti -
Ravimiamet
calcium/colecalciferol béres õhukese polümeerikattega tablett
beres pharmaceuticals ltd. - kaltsium+kolekaltsiferool - õhukese polümeerikattega tablett - 600mg+800rÜ 90tk; 600mg+800rÜ 120tk; 600mg+800rÜ 60tk; 600mg+800rÜ 30tk
Eesti -
eesti -
Ravimiamet
rcifax õhukese polümeerikattega tablett
lupin limited - rifaksimiin - õhukese polümeerikattega tablett - 200mg 100tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech
xbiotech germany gmbh - inimese iggl monoklonaalne antikeha, mis on spetsiifiline inimese interleukiin-1 alfa suhtes - kolorektaalne kasvaja - antineoplastilised ained - ravi metastaatilise kolorektaalse vähi.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
adrovance
n.v. organon - colecalciferol, alendronic acid (as sodium trihydrate) - osteoporoos, postmenopausis - narkootikumid luuhaiguste raviks - menopausijärgse osteoporoosi ravi d-vitamiini puudulikkusega patsientidel. adrovance vähendab lülisamba ja puusaluu murrud.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
locametz
novartis europharm limited - gozetotide - radionukliidi pildistamine - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.